<code id='2DD59827BA'></code><style id='2DD59827BA'></style>
    • <acronym id='2DD59827BA'></acronym>
      <center id='2DD59827BA'><center id='2DD59827BA'><tfoot id='2DD59827BA'></tfoot></center><abbr id='2DD59827BA'><dir id='2DD59827BA'><tfoot id='2DD59827BA'></tfoot><noframes id='2DD59827BA'>

    • <optgroup id='2DD59827BA'><strike id='2DD59827BA'><sup id='2DD59827BA'></sup></strike><code id='2DD59827BA'></code></optgroup>
        1. <b id='2DD59827BA'><label id='2DD59827BA'><select id='2DD59827BA'><dt id='2DD59827BA'><span id='2DD59827BA'></span></dt></select></label></b><u id='2DD59827BA'></u>
          <i id='2DD59827BA'><strike id='2DD59827BA'><tt id='2DD59827BA'><pre id='2DD59827BA'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          knowledge

          author:Wikipedia    - browse:4473

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time